Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sanofi (SNY) EBITDA (2016 - 2026)

Sanofi's EBITDA history spans 16 years, with the latest figure at $2.5 billion for Q1 2026.

  • On a quarterly basis, EBITDA rose 3.31% to $2.5 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $7.2 billion, a 15.84% decrease, with the full-year FY2025 number at $7.4 billion, down 4.71% from a year prior.
  • EBITDA hit $2.5 billion in Q1 2026 for Sanofi, up from -$5.6 billion in the prior quarter.
  • Over the last five years, EBITDA for SNY hit a ceiling of $10.9 billion in Q4 2022 and a floor of -$5.6 billion in Q4 2025.
  • Historically, EBITDA has averaged $3.0 billion across 5 years, with a median of $2.5 billion in 2026.
  • Biggest five-year swings in EBITDA: surged 544.74% in 2022 and later plummeted 1011.95% in 2025.
  • Tracing SNY's EBITDA over 5 years: stood at $10.9 billion in 2022, then plummeted by 31.12% to $7.5 billion in 2023, then tumbled by 91.82% to $612.3 million in 2024, then plummeted by 1011.95% to -$5.6 billion in 2025, then soared by 144.47% to $2.5 billion in 2026.
  • Business Quant data shows EBITDA for SNY at $2.5 billion in Q1 2026, -$5.6 billion in Q4 2025, and $8.6 billion in Q3 2025.